Soleno Therapeutics, Inc. (SLNO) Tops Q2 EPS by 55c

Soleno Therapeutics, Inc. (NASDAQ: SLNO) reported Q2 EPS of ($0.09), $0.55 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $32.7 million versus the consensus estimate of $15.35 million.

For earnings history and earnings-related data on Soleno Therapeutics, Inc. (SLNO) click here.

You May Also Be Interested In

• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• HSBC Downgrades Kakao Corp. (035720:KS) to Hold
• UBS Downgrades Converge ICT Solutions Inc (CNVRG:PM) to Neutral